GET DAILY SIGNALSMedpace Holdings (NASDAQ: MEDP) Reports Q3 Revenue and EPS Beats, but Full-Year Guidance Weighs on Shares
Key Takeaways
- Medpace Holdings reported third-quarter 2026 revenue of $716.0 million, up 8.5% year over year and slightly ahead of the roughly $714.5 million consensus estimate.
- GAAP diluted earnings per share (EPS) came in at $4.84, beating the analyst consensus of $4.44 by $0.40.
- Net new business awards rose 10.6% to $873.4 million, while backlog grew 5.6% to $3.17 billion.
- Full-year 2026 revenue guidance of $2.835–$2.855 billion landed modestly below consensus at the midpoint, pressuring shares in after-hours trading.
- Adjusted EBITDA reached $172.1 million, a 24.0% margin, while the board authorized a new $1.0 billion buyback program.
Earnings Context and Why It Matters
Medpace Holdings, Inc. (MEDP) operates as a science-driven clinical contract research organization that oversees Phase I through IV trials for pharmaceutical, biotechnology, and medical device firms. Its third-quarter results carry particular significance given the premium valuation placed on consistent bookings and backlog expansion. Earlier this year, softer first-quarter awards raised investor questions, only for a strong second-quarter rebound to restore confidence and lift shares to record levels. With about 95% of revenue coming from biotechnology clients, this report provides a useful checkpoint on whether the company’s leading margins and valuation multiple can hold as the biotech funding environment evolves.
Reported Results
For the three months ended September 30, 2026, MEDP posted net revenue of $716.0 million, an 8.5% rise from $659.9 million a year earlier and just above the $714.47 million consensus. Net income increased to $137.5 million, or $4.84 per diluted share, from $111.1 million, or $3.86 per diluted share, in the prior-year quarter. The EPS figure exceeded the $4.44 analyst consensus by $0.40, and the net income margin widened to 19.2% from 16.8%.
Operating income reached $165.5 million, expanding the operating margin to 23.1% from 21.5%. Adjusted EBITDA totaled $172.1 million for a 24.0% margin, up 16.0% year over year. Net new business awards climbed 10.6% to $873.4 million from $789.6 million, and backlog as of September 30, 2026, rose 5.6% to $3,167.2 million from $3,000.6 million.
Management set full-year 2026 revenue guidance between $2.835 billion and $2.855 billion, with a midpoint of $2.845 billion that fell slightly below the $2.852 billion consensus. GAAP EPS guidance of $17.97 to $18.32, however, exceeded the $17.72 consensus at the midpoint. The company also approved a new $1.0 billion share repurchase authorization effective October 20, 2026, replacing the prior program that had $527.0 million left.
Market Reaction and Investor Sentiment
Shares of MEDP declined about 1.9% in after-hours trading despite the EPS and revenue beats. The move appeared driven by the full-year revenue outlook, whose midpoint sat modestly below expectations. The reaction underscores how much of the valuation hinges on the sustainability of growth rather than any single quarter’s outperformance. Ahead of the release, analysts generally held a cautious stance, with most maintaining hold ratings amid questions about whether the premium forward multiple can be maintained as revenue growth moderates from recent peaks. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Forward Outlook and Key Factors to Monitor
Looking ahead, attention will turn to whether MEDP can translate the recent pickup in bookings into steady revenue growth. Backlog conversion rates and the net book-to-bill ratio will serve as important near-term signals of demand. While stronger net new awards help address earlier concerns about backlog coverage, the tempered full-year revenue guidance suggests management is taking a measured view on the pace of improvement.
Margin trends also warrant watching. The expansion of the operating margin to 23.1% reflects solid operating leverage, though questions remain about how much efficiency gains from artificial intelligence in clinical trials will benefit CROs versus their pharmaceutical clients. Maintaining industry-leading profitability will require continued cost discipline and favorable pricing.
Biotech funding conditions remain a key external variable. Given that the large majority of revenue comes from biotechnology clients, the availability of venture capital and public financing for drug developers will shape demand for new trial work. The fresh $1.0 billion repurchase authorization reflects management’s confidence in cash generation, but investors should track cash flow, customer concentration, and award momentum in upcoming quarters for the clearest indications of the longer-term path.
Exploring Tickeron’s AI Tools for Deeper Analysis
In my own research process, I’ve found Tickeron’s AI-powered tools helpful for quickly scanning market patterns and comparing companies like MEDP against peers. The platform’s customizable filters on fundamentals, technical signals, and performance metrics allow for more efficient idea generation alongside traditional fundamental work. It’s become a regular part of how I cross-check earnings-related observations and refine watchlists.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MEDP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for MEDP turned positive on October 15, 2026. Looking at past instances where MEDP's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on MEDP as a result. In 72 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
MEDP moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDP advanced for three days, in 238 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 201 of 256 cases where MEDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
MEDP broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MEDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (42.619) is normal, around the industry mean (64.450). P/E Ratio (38.183) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (2.929) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.390) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company
Industry MedicalSpecialties
Advertisement